Symbols

ROIV

Roivant Sciences·NASDAQ

--(--)

ROIV fundamentals

ROIV Q3 2026 Earnings

Roivant Sciences (ROIV) released its earnings on Feb 6, 2026: revenue was 2.00M (YoY -77.82%), missed estimates; EPS was -0.17 (YoY -173.91%), beat estimates.

Revenue / YoY

2.00M

-77.82%

EPS / YoY

-0.17

-173.91%

Report date

Feb 6, 2026

ROIV Earnings Call Summary for Q3,2026

Breakthrough Sarcoidosis Data: Brepocitinib achieved 21.6-point CSAMI improvement, 100% high-dose responders, and no safety surprises in Phase II.
Pipeline Momentum: 9+ pivotal studies readouts in 2026, including PH-ILD, D2T RA, and Graves' disease.
Financial Strength: $4.5B cash, no near-term capital needs despite ~$300M annual R&D spend.
Strategic Focus: Orphan inflammation leadership with brepocitinib (3 Phase III programs) and FcRn franchise (IMVT-1402).

Earnings

EPS

Revenue

Revenue & Expenses

ROIV has released its 2026 Q3 earnings report, with revenue of 2.00M, reflecting a YoY change of -77.83%, and net profit of -313.70M, showing a YoY change of -365.68%. The Sankey diagram below clearly presents ROIV's revenue sources and cost distribution.

Key Indicators

Roivant Sciences (ROIV) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Roivant Sciences (ROIV)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Roivant Sciences (ROIV)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Roivant Sciences (ROIV)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown